1. Home
  2. EVO vs EOLS Comparison

EVO vs EOLS Comparison

Compare EVO & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Evotec SE

EVO

Evotec SE

N/A

Current Price

$1.66

Market Cap

568.6M

Sector

Health Care

ML Signal

N/A

Logo Evolus Inc.

EOLS

Evolus Inc.

N/A

Current Price

$7.79

Market Cap

529.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EVO
EOLS
Founded
1993
2012
Country
Germany
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
568.6M
529.1M
IPO Year
2007
2018

Fundamental Metrics

Financial Performance
Metric
EVO
EOLS
Price
$1.66
$7.79
Analyst Decision
Buy
Buy
Analyst Count
3
6
Target Price
$4.17
★ $15.00
AVG Volume (30 Days)
153.5K
★ 658.0K
Earning Date
11-05-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 1.23
EPS
★ N/A
N/A
Revenue
N/A
★ $297,176,000.00
Revenue This Year
N/A
$12.44
Revenue Next Year
$20.51
$17.37
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 11.61
52 Week Low
$1.50
$3.86
52 Week High
$4.27
$9.31

Technical Indicators

Market Signals
Indicator
EVO
EOLS
Relative Strength Index (RSI) 46.64 45.13
Support Level $1.50 $7.59
Resistance Level $1.97 $8.47
Average True Range (ATR) 0.05 0.29
MACD 0.02 -0.06
Stochastic Oscillator 76.00 29.89

Price Performance

Historical Comparison
EVO
EOLS

About EVO Evotec SE

Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.

Share on Social Networks: